InvestorsHub Logo
Followers 34
Posts 2992
Boards Moderated 0
Alias Born 02/27/2016

Re: drv17 post# 134324

Thursday, 12/14/2017 2:58:22 PM

Thursday, December 14, 2017 2:58:22 PM

Post# of 458788
There’s no doubt that our Alz trial delay is partially or wholly because of the establishment of the ACTC and the guidances to come.

The ACTC will help in developing innovative trial design methods, outcomes and analysis strategies. In order for us to qualify for their funding, I bet they will be reviewing and working with us. Collaboration!

With the Aison connection and the email response, among other things ( can someone repost what he said?), I am confident we will be one of the companies to receive funding.

The poster child!! Is still a very real possibility. We have safety safety and more safety with data data and more data. Innovation!!

You can’t push ahead the Alz trials if this is coming down the pike.

Missling is not to blame. Maybe he thought this would happen sooner. Yes. He said three trials but it wasn’t a promise. Did he overpormise? Of course.

But who has the most to lose. Personally, professionally, financially, academically, etc. He Does.

So guess who wants to succeed more than anybody??
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News